Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.03 -34.7%	$0.06	$0.02 ▼ $0.80	$2.17M	1.17	4,597 shs	498 shs
BXRX Baudax Bio	$0.02	$0.02	$0.01 ▼ $3.47	$1.14M	1.57	281,029 shs	310,872 shs
NBY NovaBay Pharmaceuticals	$0.90 -0.8%	$0.66	$0.44 ▼ $1.25	$5.24M	0.4	1.42 million shs	20.90 million shs
OGEN Oragenics	$1.12	$1.73	$1.03 ▼ $40.80	$4.62M	0.65	323,505 shs	56,655 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	-3.77%	-3.77%	+46.97%	+46.13%	+155.00%
BXRX Baudax Bio	0.00%	0.00%	0.00%	0.00%	0.00%
NBY NovaBay Pharmaceuticals	-0.40%	+45.53%	+34.82%	+60.22%	+71.46%
OGEN Oragenics	+0.90%	+1.82%	-19.42%	-80.56%	-96.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BXRX Baudax Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	0.3612 of 5 stars	1.5	0.0	0.0	0.0	0.6	0.0	1.3
OGEN Oragenics	0.1726 of 5 stars	0.0	4.0	0.0	0.0	0.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
BXRX Baudax Bio	0.00	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	-5.45% Downside
OGEN Oragenics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$3.24M	0.44	N/A	N/A	($2.06) per share	-0.02
BXRX Baudax Bio	$1.27M	0.90	N/A	N/A	($14.93) per share	0.00
NBY NovaBay Pharmaceuticals	$9.78M	0.54	N/A	N/A	$4.25 per share	0.21
OGEN Oragenics	N/A	N/A	N/A	N/A	$0.61 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	-$48.07M	-$7.98	N/A	∞	N/A	N/A	N/A	N/A	N/A
BXRX Baudax Bio	-$58.79M	-$9.23	N/A	N/A	N/A	N/A	N/A	-175.11%	N/A
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A
OGEN Oragenics	-$20.66M	-$21.42	N/A	∞	N/A	N/A	-2,087.95%	-486.56%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BXRX Baudax Bio	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGEN Oragenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
BXRX Baudax Bio	N/A	0.07	0.07
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91
OGEN Oragenics	N/A	1.93	1.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
BXRX Baudax Bio	9.05%
NBY NovaBay Pharmaceuticals	23.25%
OGEN Oragenics	18.71%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
BXRX Baudax Bio	0.10%
NBY NovaBay Pharmaceuticals	0.10%
OGEN Oragenics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	20	42.63 million	42.36 million	Not Optionable
BXRX Baudax Bio	9	52.46 million	52.41 million	Not Optionable
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable
OGEN Oragenics	5	4.13 million	10.98 million	N/A

BXRX, OGEN, NBY, and ADXS Headlines

Recent News About These Companies

Oragenics Q2 2025 Shareholder Update

August 11, 2025 | globenewswire.com

Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

July 31, 2025 | finance.yahoo.com

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

July 16, 2025 | globenewswire.com

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - Seeking Alpha

July 3, 2025 | seekingalpha.com

Oragenics stock tumbles after announcing $20 million preferred stock offering

July 2, 2025 | investing.com

Oragenics Completes Approximately $16.5 Million Offering

July 2, 2025 | globenewswire.com

Sarasota biotech company announces $20M public offering

July 2, 2025 | businessobserverfl.comB

Oragenics shares plunge following announcement of $20 million preferred stock sale

July 1, 2025 | msn.com

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

July 1, 2025 | globenewswire.com

Oragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

June 11, 2025 | nasdaq.com

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

June 10, 2025 | finance.yahoo.com

Oragenics Inc.

June 4, 2025 | wsj.com

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split

May 29, 2025 | finance.yahoo.com

Oragenics Hosts Neurotrauma Medicine Webinar Presentation

May 20, 2025 | tipranks.com

Oragenics gains Australia’s nod for concussion therapy trial

May 15, 2025 | uk.investing.com

Oragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion Treatment

May 14, 2025 | nasdaq.com

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025 | globenewswire.com

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion ...

May 12, 2025 | gurufocus.com

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025 | globenewswire.com

Oragenics Appoints Janet Huffman as CEO and CFO

May 2, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BXRX, OGEN, NBY, and ADXS Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

$0.03 -0.02 (-34.71%)

As of 09:53 AM Eastern

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Baudax Bio NASDAQ:BXRX

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

NovaBay Pharmaceuticals NYSE:NBY

$0.90 -0.01 (-0.83%)

As of 03:59 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Oragenics NYSE:OGEN

$1.12 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.12 0.00 (-0.36%)

As of 07:52 PM Eastern

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time